# Multiple Sclerosis

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred         |
| :---------------- |
| Aubagio           |
| Avonex            |
| Betaseron         |
| Copaxone BvG      |
| Dalfampridine     |
| Dimethyl Fumarate |
| Gilenya           |
| Rebif             |

### Non-Preferred

| Non-Preferred |
| :------------ |
| Bafiertam     |
| Extavia       |
| Glatiramer    |
| Glatopa       |
| Kesimpta      |
| Mavenclad     |
| Mayzent       |
| Plegridy      |
| Ponvory       |
| Vumerity      |
| Zeposia       |

## Length of Authorizations

365 Days

## Grandfathering

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

## Prior Authorization Criteria

1.  Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
    -   Allergy to medications not requiring prior approval
    -   Contraindication to or drug interaction with medications not requiring prior approval
    -   History of unacceptable/toxic side effects to medications not requiring prior approval
2.  The requested medication may be approved if there has been a therapeutic failure to no less than a **30-day** trial on at least **one** medication not requiring prior approval.

## Additional Criteria

### Mayzent

Additional Mayzent Requirements

- Must review liver function tests (LFTS) complete blood count (CBC), ophthalmic examination, varicella zoster virus antibodies, and electrocardiogram (ECG) prior to initiation. Must confirm patient is not CYP2C9\*3\*3 genotype. Dose limited to 2mg/day.

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=38)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=16)
